Pfizer tests where to inject new Weight-Loss drug for best effect
NCT ID NCT07400679
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single dose of the experimental drug PF-08653944 in 54 overweight or obese adults. Researchers want to see how the drug is absorbed when injected into the abdomen, thigh, or upper arm. The study also monitors safety through blood tests and vital signs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-08653944 (also called MET097)
What this could lead to
If successful, this study could help determine the best injection site for future trials of this medicine for weight management.
What could go wrong
This is an early Phase 1 study with only 54 participants, so results may not apply to larger populations. The medicine may cause side effects like changes in blood tests.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New Haven Clinical Research Unit
New Haven, Connecticut, 06511, United States